A pilot study of allogeneic hematopoietic stem cell transplantation for intermediated-risk acute myeloid leukemia patients

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally recommended as consolidation after first complete remission (CR1). In real-world, alloSCT might not be readily available, but there is paucity of data on the optimal timing of alloSCT for these patients. Patients and Methods: In this pilot study, we compared the outcomes of 13 patients undergoing alloSCT in CR1 with 13 patients undergoing alloSCT after relapse (non-CR1) to examine whether upfront alloSCT yields a better prognosis. Results: There were no differences between the two groups with regards to relapse-free survival (p=0.507) and overall survival (p=0.798). There were more chronic graft-versus-host-disease (GVHD) in the CR1 group compared to the non-CR group (p=0.001), but no difference in acute GVHD. Conclusion: The outcome of alloSCT after relapse is not inferior to that of alloSCT in CR1, supporting the role of alloSCT after relapse in the setting of limited donors and resources.

Original languageEnglish
Pages (from-to)617-622
Number of pages6
JournalIn Vivo
Volume35
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • Acute myeloid leukemia
  • Allogeneic hematopoietic stem cell transplantation
  • Intermediate risk

Fingerprint Dive into the research topics of 'A pilot study of allogeneic hematopoietic stem cell transplantation for intermediated-risk acute myeloid leukemia patients'. Together they form a unique fingerprint.

Cite this